Inspired by people.
Driven by purpose.
At Glucotrack, our mission is to reimagine continuous glucose monitoring through innovative research and thoughtful design. Our investigational CBGM technology is being developed with the goal of integrating continuous blood glucose sensing into daily life—without the need for external wearables. Rooted in a people-first approach, we are exploring solutions intended to be less disruptive and more intuitive for people living with diabetes.
A legacy of innovation
While Glucotrack was established in 2021, our roots date back to the early 2000s when we first embarked on the journey to innovate glucose monitoring technology. With extensive expertise in glucose sensing, medical device development, and patented inventions, our leaders embody a spirit of innovation aimed at shaping the future of diabetes care. As the field continues to evolve, so do we. Today, we are developing an investigational CBGM system designed to be evaluated for its potential to offer a new approach to long-term glycemic monitoring—for people with diabetes and the healthcare professionals who support them.
Our leadership team
The collective expertise and achievements of our leadership team drive our strategic direction, ensuring that we remain at the cutting edge of technological advancements in diabetes care.
Clinical and Scientific Advisors
Leveraging their deep clinical and scientific expertise, our advisors provide independent strategic insights and guidance to help us shape the future of diabetes care.
David S. Hirsh, MD – Medical Director, Cardiology
David Hirsh is a cardiac electrophysiologist at the Harbin Clinic Cardiology in Rome, GA. Prior to joining Harbin Clinical, Dr. Hirsh served as an Associate Professor of Medicine in the Division of Cardiology at Emory University School of Medicine, as the Director of Clinical Cardiac Electrophysiology at Grady Memorial Hospital, where he started the electrophysiology laboratory at Atlanta’s large public hospital, and as clinical cardiac electrophysiologist at the Atlanta VA Medical Center.
David C. Klonoff, MD – Chair, Scientific Advisory Board
David Klonoff is an endocrinologist specializing in the development and use of diabetes technology. He is a Clinical Professor of Medicine at the University of California, San Francisco and Director of the Diabetes Research Institute at Sutter Health’s Mills-Peninsula Medical Center. He is also Editor-in-Chief of the Journal of Diabetes Science and Technology. Dr. Klonoff founded Diabetes Technology Society, a nonprofit organization committed to promoting development and use of technology in the fight against diabetes. He received the American Diabetes Association’s Outstanding Physician-Clinician award in 2019 and an FDA Director’s Citation in 2012.
Usman Latif, MD, MBA – Clinical Advisor, Integrated Glucose Applications
Usman Latif is an Associate Professor in the Department of Anesthesiology, Pain and Perioperative Medicine, at The University of Kansas Medical Center and a Board-Certified Anesthesiologist at The University of Kansas Health System. He previously served as faculty at Yale University School of Medicine, where he worked as a Sub-Investigator at the Pfizer Clinical Research Unit. He holds an MBA and a certificate in Value-Based Healthcare from Harvard Business School and has published extensively. His research focuses on neuromodulation, innovative technology applications, AI, and data-driven medical advances.
Guillermo Umpierrez, MD – Chair, Medical Advisory Board
Guillermo Umpierrez is a Professor of Medicine in the division of endocrinology and metabolism at Emory University School of Medicine and a former president of the American Diabetes Association for Medicine and Science. He is a clinician-scientist with extensive experience conducting clinical and population-based research on diabetes. As Editor-in-Chief of the American Diabetes Association Therapy for Diabetes Mellitus and Related Disorders textbook, he has published over 550 scientific manuscripts and book chapters. Among his many roles, he serves as Director of the Emory Latino Diabetes Education Program, a nationally accredited Spanish diabetes education program.
Board of Directors
Luis J Malavé (Chairman)
With over 30 years of leadership in the med tech industry, Luis Malavé specializes in diabetes management across all company stages. He excels in product development, operations, marketing, strategic partnerships, and FDA regulatory strategy.
Currently serving as president of EOFlow Co. Ltd., Luis previously led Palyon Medical and spent nearly a decade at Insulet, where he held various senior roles. He also has experience at Medtronic and MiniMed.
Luis holds a BS in Mathematics and Computer Science from the University of Minnesota, a Master’s in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland.
Andy Balo
Andy Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. He was part of the original executive team at Dexcom and played a critical role in shaping the company’s future. During his tenure of 22 years, he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide and coordinated quality activities across multiple manufacturing facilities. In March 2024, Mr. Andy retired from Dexcom as Executive Vice President of Clinical, Global Access, and Medical Affairs. Andy has also held leadership roles at St. Jude Medical, Baxter, Pacesetter and Endocardial Solutions.
Andy holds a Bachelor of Science degree in microbiology and chemistry from the University of Maryland and completed graduate studies at UCLA.
Erin Carter
Erin Carter brings more than 30 years of executive-level finance experience in the medical device and healthcare industries. She held various senior roles at Medtronic, including CFO and Vice President of Finance for their $9B neuroscience portfolio. Notably, she grew the Gastrointestinal Solutions division from a $36M startup to $450M in 5 years through organic growth and acquisitions.
Prior to Medtronic, Erin served at Boston Scientific and UnitedHealth Group. She played a key role at Arterial Vascular Engineering, guiding its rapid growth and subsequent sale to Medtronic.
Erin holds a BA in Business Administration from California Polytechnic State University and is a Certified Public Accountant (inactive) in the State of California.
Victoria Carr-Brendel
Victoria Carr-Brendel is an accomplished executive who served as President and Group Vice President of Cochlear Implants at Sonova Group from 2018 to 2024. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer’s interventional radiology division in 2014. She started her career as a scientist in R&D with roles at Dexcom and Baxter Healthcare, amassing over forty patents and taking on increasingly senior business and management roles.
Vicky holds a BA in Biology from Monmouth College, an MS in Microbiology from Iowa State University, and a PhD in Microbiology and Immunology from the University of Illinois at Chicago.